Список литературы

1. Neufeld E., Muenzer J. The mucopolysaccharidoses// In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Basis of Inherited Disease. 8 ed. New York. NY: McGraw-Hill. 2001. P. 3421 - 52.

2. Scarpa M., Almassy Z., Beck M. et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease// Orphanet J Rare Dis. 2011. V. 6. P. 72 - 7.

3. Muenzer J., Jones S.A., Tylki-Szymanska A. et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry// Orphanet J Rare Dis. 2017. V. 12. N 1. P. 82.

4. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders//JAMA. 1999. V. 281. P. 249 - 54.

5. Martin R., Beck M., Eng C., Giugliani R., Harmatz P., Mufioz V. et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)// Pediatrics. 2008. V. 121. P. 377 - 86.

6. Simmons M.A., Bruce I.A., Penney S., Wraith E., Rothera M.P. Otorhinolaryngological manifestations of the mucopolysaccharidoses// Int. J. Pediatr. Otorhinolaryngol. 2005. V. 69. P. 589 - 95.

7. Biswas J., Nandi K., Sridharan S., Ranjan P. Ocular manifestation of storage diseases// Curr. Opin. Ophthalmol. 2008. V. 19. P. 507 - 11.

8. Thappa D.M., Singh A., Jaisankar T.J., Rao R., Ratnakar C. Pebbling of the Skin: A Marker of Hunter"s Syndrome// Pediatric Dermatology. 1998. V. 15. N 5. P. 370 - 3.

9. Barbier A.J., Bielefeld B., Whiteman D.A. et al. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase// Mol Genet Metab. 2013. V. 110. N 3. P. 303 - 10.

10. Kim C., Seo J., Chung Y., Ji H.J., Lee J., Sohn J. Comparative study of idursulfase beta and idursulfase in vitro and in vivo// J. Hum. Genet. 2017. V. 62. P. 167 - 74.

11. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders// Int J Clin Pharmacol Ther. 2009. V. 47. N 1. P. 100 - 6.

12. Wraith J.E., Scarpa M., Beck M. et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy// Eur J Pediatr. 2008. V. 167. P. 267 - 77.

13. Sampayo-Cordero M., Miguel-Huguet B., Pardo-Mateos A. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases// Orphanet J Rare Dis. 2019. V. 14. N 1. P. 230.

14. Bradley L., Haddow H., Palomaki G. Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review// Genet Med. 2017. V. 19. P. 1187 - 1201.

15. Da Silva E.M.K. et al. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome) //Cochrane Database of Systematic Reviews. 2016. N 2.

16. Giugliani R., Federhen A., Rojas M.V. et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment// Genet Mol Biol. 2010. V. 33. N 4. P. 589 - 604.

17. Rezende M.M. et al. Brazilian reference values for MPS II screening in dried blood spots - A fluorimetric assay //Clinical biochemistry. 2014. V. 47. N 13 - 14. P. 1297 - 9.

18. Human Gene Mutations Database. Qiagen HGMD Professional.

19. Okuyama T., Tanaka A., Suzuki Y. et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II)// Mol Genet Metab. 2010. V. 99. P. 18 - 25.

20. Guffon N., Heron B., Chabrol B. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study// Orphanet J Rare Dis. 2015. V. 10. P. 43.

21. Jurecka A., Zuberuber Z., Opoka-Winiarska V. et al. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature// Mol Genet Metab. 2012. V. 107. P. 508 - 12.

22. Миронов С.П., Колесов С.В., Переверзев В.С., Колбовский Д.А., Кулешов А.А., Ветрилэ М.С., Казьмин А.И. Опыт хирургического лечения краниовертебрального стеноза у пациентов с мукополисахаридозом I, II, VI типов// Хирургия позвоночника. 2018. Т. 15. N 4. С. 32 - 40.

23. Williams N., Challoumas D., Eastwood D.M. Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses? // Journal of Children"s Orthopaedics. 2017. V. 11. N 4. P. 289 - 97.

24. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders //International journal of clinical pharmacology and therapeutics. 2009. V. 47. P. S100 - 6.

25. Mendelsohn N.J., Harmatz P., Bodamer O. et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome Survey// Genetics in Medicine. 2010. V. 12. N 12. P. 816 - 22.

26. Remondino R.G. et al. Clinical Manifestations and Surgical Management of Spinal Lesions in Patients With Mucopolysaccharidosis: A Report of 52 Cases //Spine deformity. 2019. V. 7. N. 2. P. 298 - 303.

27. Kwon JY, Ko K, Sohn YB, et al. High prevalence of carpal tunnel syndrome in children with mucopolysaccharidosis type II (Hunter syndrome). Am J Med Genet A. 2011; 155A: 1329 - 1335.